RedHill Biopharma Ltd. (NASDAQ:RDHL) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to US$2.74 in the week after its latest quarterly results. Revenues of US$22m came in a modest 7.7% below forecasts. Statutory losses were a relative bright spot though, with a per-share loss of US$0.05 […]